177Lu-Dotatate Radioequivalent Earns Final FDA Approval in GEP-NETs

The FDA has granted final approval to lutetium Lu 177 dotatate (Bravnetsa; ¹⁷⁷Lu-dotatate), a radioequivalent to ¹⁷⁷Lu-dotatate (Lutathera), for the treatment of adult patients with somatostatin receptor–positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs.¹

Previously known as PNT2003, the product has been determined as bioequivalent and therapeutically equivalent to the reference agent, providing an additional FDA-approved radiopharmaceutical option for this patient population.

The latest decision converts the radioequivalent’s tentative approval, issued in March 2026, into a full approval. The approval was granted through the FDA’s Abbreviated New Drug Application (ANDA) pathway, making the agent the first radioligand therapy fully approved through this pathway.

“This approval…gives clinicians another FDA-approved option to support treatment decisions based on each patient’s needs,” Ludger Dinkelborg, PhD, head of research and development at Lantheus, stated in a news release.¹

Clinical Context

¹⁷⁷Lu-dotatate is a peptide receptor radionuclide therapy that targets somatostatin receptor 2 (SSTR2), which is commonly expressed on neuroendocrine tumor cells. After binding to the receptor, the radioligand is internalized and delivers beta-minus radiation to the tumor cell.

The clinical foundation for ¹⁷⁷Lu-dotatate was established in the phase 3 NETTER-1 trial (NCT01578239), which evaluated the treatment in patients with progressive, SSTR+ midgut NETs. In the initial analysis, ¹⁷⁷Lu-dotatate plus long-acting octreotide (Sandostatin LAR) reduced the risk of disease progression or death compared with high-dose long-acting octreotide alone.² Twenty-month progression-free survival was 65.2% vs 10.8%, respectively, whereas objective response rates were 18% vs 3%.

These findings supported the FDA’s January 2018 approval of ¹⁷⁷Lu-dotatate for adults with SSTR+ GEP-NETs. At that time, the treatment represented a new therapeutic approach for patients with advanced disease progressing on somatostatin analog therapy.

Long-term NETTER-1 data subsequently showed that the difference in median overall survival was not statistically significant, although median survival was numerically 11.7 months longer with ¹⁷⁷Lu-dotatate.³ The long-term safety profile included adverse events such as nausea, vomiting, fatigue, and myelosuppression.

Safety and Treatment Considerations

The safety considerations associated with ¹⁷⁷Lu-dotatate remain relevant with the radioequivalent. In NETTER-1, anemia occurred in 81% of patients receiving ¹⁷⁷Lu-dotatate with long-acting octreotide compared with 54% of those receiving high-dose long-acting octreotide; thrombocytopenia occurred in 53% vs 17%, and neutropenia occurred in 26% vs 11%. Grade 3 or 4 anemia events occurred in 0% vs 1%, 1% vs 0% for thrombocytopenia, and 3% vs 0% for neutropenia.

Radiation safety is also an important component of treatment. Radioactivity may be detected in urine for up to 30 days after administration, and precautions are recommended to minimize radiation exposure to patients, healthcare personnel, and household contacts.

The prescribing information includes additional warnings and precautions for secondary myelodysplastic syndrome and leukemia, renal and hepatic toxicity, hypersensitivity reactions, neuroendocrine hormonal crisis, embryo-fetal toxicity, and infertility.¹ These considerations, along with radiation-safety procedures and laboratory monitoring, remain important components of care as the ¹⁷⁷Lu-dotatate radioequivalent is incorporated into treatment for eligible patients with SSTR+ GEP-NETs.

REFERENCES

1. Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs. News release. September 22, 2026. Accessed September 23, 2026. https://tinyurl.com/ymvsubyf

2. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427

3. Strosberg JR, Caplin ME, Kunz PL, et al. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6